Founded in 2011 and headquartered in the United States, Xeragenx is at the forefront of the biotechnology industry, with its innovative approach to utilizing Intrinsic Factor. This development holds immense potential in improving protein stability, facilitating oral absorption, and achieving 'Precision Liver Targeting'. Additionally, Intrinsic Factor offers opportunities in high sensitivity analytic tests and imaging, promising to enhance existing tests and introduce new ones.
Despite the lack of specific information regarding the last investment and investors, the ground-breaking work and potential of Xeragenx in the biotechnology industry position it as an attractive prospect for venture capital engagement.
Xeragenx
A biotech company committed to improving global health by “Reinventing B12”
Founded 2011
Saint Louis, United States
1 employees
Biotechnology
Saint Louis, United States
1 employees
Biotechnology
General Information
Company Name
Xeragenx
Founded Year
2011
Location
Saint Louis, United States
Saint Louis, United States
Employees
1
Industries
Biotechnology
BounceWatch is an independent company data service, not affiliated with Xeragenx. To contact Xeragenx, visit xeragenx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Xeragenx compare?
A PDF of Xeragenx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Xeragenx soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Xeragenx
Business keywords: Recombinant DNA technology, Drug delivery, Healthcare innovation, Biopharmaceuticals, Intrinsic Factor, Protein stability, Oral absorption, Precision medicine, Diagnostic tests, Imaging technology, Food science, Nutraceuticals, Plant-derived products
No funding data available for Xeragenx yet.
Xeragenx Alternatives & Competitors
View All Alternatives
Xeragenx vs
Leveraging innovative technology to convert injectable drugs into oral treatments for enhanced absor...
Post-IPO Equity
Biopharma, Biotechnology
Xeragenx vs
SeraCare
United States
LGC Clinical Diagnostics | Science for a Safer World
Private Equity
111 employees
Biotechnology, Health Care
Xeragenx vs
Innovative solutions for precise MRI imaging and cancer treatment with advanced drug delivery and li...
Venture round
1 employees
Biotechnology, Life Sciences
FAQ About Xeragenx
A biotech company committed to improving global health by “Reinventing B12”
Xeragenx was founded in 2011.
Xeragenx is headquartered in Saint Louis, United States.
Xeragenx operates in Biotechnology. Its work centres on Recombinant DNA technology, Drug delivery, Healthcare innovation and Biopharmaceuticals.
Xeragenx has approximately 1 employees.
Top alternatives and competitors to Xeragenx include Chiasma, SeraCare, Photobiotics, Brainomix, Imaginostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xeragenx and Chiasma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Xeragenx, https://bouncewatch.com/company/xeragenx, updated 27 October 2024. When citing, please name BounceWatch and link this page.
